Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 8/2018

01-08-2018 | Nephrology - Original Paper

Silencing of CXCL12 performs a protective effect on C5b-9-induced injury in podocytes

Authors: Wengang Sha, Lei Shen, Ling Zhou, Deyu Xu, Jing Yang, Guoyuan Lu

Published in: International Urology and Nephrology | Issue 8/2018

Login to get access

Abstract

Purpose

Podocytes, terminal differentiation cell in glomerulu, are crucial to kidney-related diseases such as membranous nephropathy (MN). MN is characterized by podocyte injury and glomerular basement membrane thickening. This paper focused to investigate the expression of chemokine (C-X-C motif) ligand 12 (CXCL12) in MN patients and its possible role in podocyte injury.

Methods

Through the enzyme-linked immunosorbent assay, CXCL12 level in the serum and urine of MN patients was examined. Further, several assays of cell viability, apoptosis, quantitative real-time PCR and western blot were applied to explore the effects of CXCL12 in the model of podocyte injury.

Results

We found a significant increase of CXCL12 in serum and urine of MN patients, which indicated that CXCL12 may be involved in the progression of MN. And in vitro C5b-9-induced podocyte injury model, the proliferation of podocytes was inhibited whereas CXCL12/CXCR4 and phosphorylated STAT3 (p-STAT3) were increased. Silencing of CXCL12 remarkably promoted cell proliferation, inhibited cell apoptosis and suppressed CXCL12/CXCR4, p-STAT3 and caspase 3. Consistently, STAT3 inhibitor and berberine (a CXCL12 antagonist) also reduced CXCL12 treatment-induced apoptosis.

Conclusions

All data suggested that silencing of CXCL12 had a protective effect on podocyte injury, which may be through inhibiting CXCL12/STAT3 signaling pathway.
Literature
1.
Ayalon R Jr, Beck LH Jr (2015) Membranous nephropathy: not just a disease for adults. Pediatr Nephrol 30(1):31–39CrossRefPubMed
2.
Nachman P, Jennette J, Falk R (2008) Primary glomerular disease. In: Brenner BM (ed) Brenner and Rector’s The Kidney. Saunders, Philadelphia, PA, pp 987–1066
3.
Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14(7):1851–1857CrossRefPubMed
4.
Sinico RA, Mezzina N, Trezzi B, Ghiggeri G, Radice A (2016) Immunology of membranous nephropathy: from animal models to humans. Clin Exp Immunol 183(2):157CrossRefPubMed
5.
Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G, Ronco PM (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346(26):2053CrossRefPubMed
6.
Kuroki A (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (NEJM) 361(1):11–21CrossRef
7.
Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Kai F, Helmchen U, Stahl RAK (2011) An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transp 26(8):2526–2532CrossRef
8.
Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L (2010) Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol (JASN) 21(3):507CrossRef
9.
Murtas C, Ravani P, Ghiggeri GM (2011) New insights into membranous glomerulonephritis: from bench to bedside. Nephrol Dial Transp 26(8):2428CrossRef
10.
Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M, Gatti R, Argentiero L, Magistroni R, Garibotto G (2011) Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics 74(10):2008–2017CrossRefPubMed
11.
Burns JM, Summers BC, Yu W, Melikian A, Berahovich R, Miao Z, Penfold MET, Sunshine MJ, Dan RL, Kuo CJ (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203(9):2201CrossRefPubMedPubMedCentral
12.
Sayyed SG, Hägele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders HJ (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52(11):2445–2454CrossRefPubMed
13.
Liao X, Pirapakaran T, Luo XM (2016) Chemokines and chemokine receptors in the development of lupus nephritis. Mediat Inflamm (2, article e63)
14.
Schramme A, Abdelbakky MS, Gutwein P, Obermüller N, Baer PC, Hauser IA, Ludwig A, Gauer S, Schäfer L, Sobkowiak E (2008) Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int 74(3):328–338CrossRefPubMed
15.
16.
Gutwein P, Abdel-Bakky MS, Schramme A, Kai D, Kämpfer-Kolb N, Amann K, Hauser IA, Obermüller N, Bartel C, Abdel-Aziz AAH (2009) CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol 174(6):2061–2072CrossRefPubMedPubMedCentral
17.
18.
Wegenka UM, Buschmann J, Lütticken C, Heinrich PC, Horn F (1993) Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13(1):276–288CrossRefPubMedPubMedCentral
19.
Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T (1994) Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263(5143):89CrossRefPubMed
20.
Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T (1994) Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77(1):63CrossRefPubMed
21.
Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282(28):20059CrossRefPubMed
22.
Dai Y, Gu L, Yuan W, Yu Q, Ni Z, Ross MJ, Kaufman L, Xiong H, Salant DJ, He JC, Chuang PY (2013) Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis. Kidney Int 84(5):950–961CrossRefPubMedPubMedCentral
23.
Feng X, Lu TC, Chuang PY, Fang W, Ratnam K, Xiong H, Ouyang X, Shen Y, Levy DE, Hyink D (2009) Reduction of Stat3 activity attenuates HIV-induced kidney injury. J Am Soc Nephrol (JASN) 20(10):2138CrossRef
24.
Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou MM, Chuang PY, He JC (2014) Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63(7):2440–2453CrossRefPubMedPubMedCentral
25.
Zhang W, Chen X, Shi S, Wei R, Wang J, Yamanaka N, Hong Q (2005) Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril. Nephrol Dial Transp 20(5):892CrossRef
26.
Arakawa T, Masaki T, Hirai T, Doi S, Kuratsune M, Arihiro K, Kohno N, Yorioka N (2008) Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis. Nephrol Dial Transp 23(11):3418–3426CrossRef
27.
He JC, Husain M, Sunamoto M, D’Agati VD, Klotman ME, Iyengar R, Klotman PE (2004) Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Investig 114(5):643–651CrossRefPubMed
28.
Liu X, Xiao Q, Bai X, Yu Z, Sun M, Zhao H, Mi X, Wang E, Yao W, Jin F (2014) Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer. Oncol Rep 32(6):2760CrossRefPubMed
29.
30.
Hong JY, Kang B, Ahyoun K, Seoyeon H, Jinhee A, Sunhwa L, Jonghyen K, Jae-Hak P, Doo-Sung C (2011) Development of a highly sensitive real-time one step RT-PCR combined complementary locked primer technology and conjugated minor groove binder probe. Virol J 8(1):1–6CrossRef
31.
Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ (2003) DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Investig 111(6):877CrossRefPubMed
32.
Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak J, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Neurath MF (2010) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. https://​doi.​org/​10.​1038/​nm1110-1341 CrossRef
33.
Mitsuyama K, Matsumoto S, Rosejohn S, Suzuki A, Hara T, Tomiyasu N, Handa K, Tsuruta O, Funabashi H, Scheller J (2006) STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55(9):1263–1269CrossRefPubMedPubMedCentral
34.
Finotto S, Eigenbrod T, Karwot R, Boross I, Doganci A, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Rosejohn S (2007) Local blockade of IL-6R signaling induces lung CD4+T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol 19(6):685–693CrossRefPubMed
35.
Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J (2008) Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3):1021CrossRefPubMed
36.
Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rosejohn S, Kado S, Takada T (2010) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184(3):1543–1551CrossRefPubMed
37.
Greenhill CJ, Rosejohn S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, Mansell A, Jenkins BJ (2010) IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 52(1–2):1199
38.
Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19(4):456–469CrossRefPubMed
39.
Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML (2011) IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 71(2):424–434CrossRefPubMed
40.
Jasiewicz M, Knapp M, Waszkiewicz E, Ptaszynska-Kopczynska K, Szpakowicz A, Sobkowicz B, Musial WJ, Kaminski KA (2015) Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. Cytokine 76(2):187–192CrossRefPubMed
41.
Dalla VM, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, Plebani M, Fioretto P (2005) Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol (JASN) 16(Suppl 1):S78CrossRef
42.
Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, Endoh M, Nomoto Y, Sakai H (1995) In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44(10):1233–1238CrossRefPubMed
Metadata
Title
Silencing of CXCL12 performs a protective effect on C5b-9-induced injury in podocytes
Authors
Wengang Sha
Lei Shen
Ling Zhou
Deyu Xu
Jing Yang
Guoyuan Lu
Publication date
01-08-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1799-8

Other articles of this Issue 8/2018

International Urology and Nephrology 8/2018 Go to the issue

Nephrology - Original Paper

The effect of periodontal disease treatment in patients with continuous ambulatory peritoneal dialysis

Urology - Original Paper

Sentinel lymph node dissection in prostate cancer using superparamagnetic particles of iron oxide: early clinical experience

Urology - Original Paper

Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population

Nephrology - Review

A holistic approach to factors affecting depression in haemodialysis patients

Nephrology - Original Paper

Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis

Nephrology - Original Paper

Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits